Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial
Background: The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin. Materials and Methods:...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2017;volume=22;issue=1;spage=39;epage=39;aulast=Heydari |
| _version_ | 1818019606914138112 |
|---|---|
| author | Behrooz Heydari Hossein Khalili Mohammad-Taghi Beigmohammadi Alireza Abdollahi Iman Karimzadeh |
| author_facet | Behrooz Heydari Hossein Khalili Mohammad-Taghi Beigmohammadi Alireza Abdollahi Iman Karimzadeh |
| author_sort | Behrooz Heydari |
| collection | DOAJ |
| description | Background: The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin. Materials and Methods: In this double-blinded randomized clinical trial, fifty patients (25 in each group) receiving amikacin (15 mg/kg/day) were randomly assigned to either atorvastatin (40 mg/day) or placebo (40 mg/day) groups for 7 days. Blood urea nitrogen (BUN), serum creatinine (SCr), and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels were measured at days 0, 1, and 7 of amikacin treatment. Results: During the study period, 4 (8%) patients including two patients in each atorvastatin and placebo group experienced AKI. Urine NGAL/urine Cr did not change significantly between and within placebo and atorvastatin groups during the study period. Similarly, the mean changes in SCr, BUN, and urine NGAL/urine Cr values did not differ significantly between and within patients with and without AKI. Conclusion: Our data suggested that the changing pattern of urine NGAL/urine Cr ratio did not differ significantly between the atorvastatin and placebo groups during the early phase of amikacin treatment. |
| first_indexed | 2024-04-14T07:54:33Z |
| format | Article |
| id | doaj.art-32b206d9258c46c3ab912fafadb89798 |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-04-14T07:54:33Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-32b206d9258c46c3ab912fafadb897982022-12-22T02:05:05ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362017-01-01221393910.4103/1735-1995.202150Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trialBehrooz HeydariHossein KhaliliMohammad-Taghi BeigmohammadiAlireza AbdollahiIman KarimzadehBackground: The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin. Materials and Methods: In this double-blinded randomized clinical trial, fifty patients (25 in each group) receiving amikacin (15 mg/kg/day) were randomly assigned to either atorvastatin (40 mg/day) or placebo (40 mg/day) groups for 7 days. Blood urea nitrogen (BUN), serum creatinine (SCr), and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels were measured at days 0, 1, and 7 of amikacin treatment. Results: During the study period, 4 (8%) patients including two patients in each atorvastatin and placebo group experienced AKI. Urine NGAL/urine Cr did not change significantly between and within placebo and atorvastatin groups during the study period. Similarly, the mean changes in SCr, BUN, and urine NGAL/urine Cr values did not differ significantly between and within patients with and without AKI. Conclusion: Our data suggested that the changing pattern of urine NGAL/urine Cr ratio did not differ significantly between the atorvastatin and placebo groups during the early phase of amikacin treatment.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2017;volume=22;issue=1;spage=39;epage=39;aulast=HeydariAcute kidney injuryamikacinatorvastatinbiomarkers |
| spellingShingle | Behrooz Heydari Hossein Khalili Mohammad-Taghi Beigmohammadi Alireza Abdollahi Iman Karimzadeh Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial Journal of Research in Medical Sciences Acute kidney injury amikacin atorvastatin biomarkers |
| title | Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial |
| title_full | Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial |
| title_fullStr | Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial |
| title_full_unstemmed | Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial |
| title_short | Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial |
| title_sort | effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients a pilot randomized placebo controlled clinical trial |
| topic | Acute kidney injury amikacin atorvastatin biomarkers |
| url | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2017;volume=22;issue=1;spage=39;epage=39;aulast=Heydari |
| work_keys_str_mv | AT behroozheydari effectsofatorvastatinonbiomarkersofacutekidneyinjuryinamikacinrecipientsapilotrandomizedplacebocontrolledclinicaltrial AT hosseinkhalili effectsofatorvastatinonbiomarkersofacutekidneyinjuryinamikacinrecipientsapilotrandomizedplacebocontrolledclinicaltrial AT mohammadtaghibeigmohammadi effectsofatorvastatinonbiomarkersofacutekidneyinjuryinamikacinrecipientsapilotrandomizedplacebocontrolledclinicaltrial AT alirezaabdollahi effectsofatorvastatinonbiomarkersofacutekidneyinjuryinamikacinrecipientsapilotrandomizedplacebocontrolledclinicaltrial AT imankarimzadeh effectsofatorvastatinonbiomarkersofacutekidneyinjuryinamikacinrecipientsapilotrandomizedplacebocontrolledclinicaltrial |